Abstract
The pharmacokinetics of chlormethiazole were studied in eight patients with advanced cirrhosis of the liver and in six healthy volunteers after oral and intravenous administration of the drug. In the patients the systemic bioavailability of oral chlormethiazole was increased about tenfold, whereas its elimination was only slightly retarded. The increased bioavailability was clearly due to decreased first-pass metabolism of chlormethiazole in the cirrhotic liver. The results indicate that chlormethiazole should be used in reduced dosage when given by mouth to patients with cirrhosis of the liver.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Jostell K. G., Agurell S., Hollister L. E., Wermuth B. Kinetics of chlormethiazole in patients with alcohol withdrawal manifestations. Clin Pharmacol Ther. 1978 Feb;23(2):181–187. doi: 10.1002/cpt1978232181. [DOI] [PubMed] [Google Scholar]
- Pentikäinen P. J., Valtonen V. V., Miettinen T. A. Deaths in connection with chlormethiazole (heminevrin) therapy. Int J Clin Pharmacol Biopharm. 1976 Oct;14(3):225–230. [PubMed] [Google Scholar]
- Shand D. G., Rangno R. E. The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacology. 1972;7(3):159–168. doi: 10.1159/000136285. [DOI] [PubMed] [Google Scholar]
- Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]